Magnet zaps fat and sugar: new surgery could beat daily meds

NCT ID NCT07317115

Recruiting now Disease control Sponsor: GT Metabolic Solutions, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new magnetic device that creates a shortcut in the gut to help with weight loss and blood sugar control, comparing it to the popular drug semaglutide (Ozempic/Wegovy). Twenty adults with obesity and type 2 diabetes will be randomly assigned to either the one-time magnetic procedure or weekly injections. The goal is to see which approach better improves diabetes and weight over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Magnet System (device) and semaglutide (drug)
What this could lead to: If the magnetic procedure works, it could offer a less invasive, one-time alternative to daily medication for managing obesity and type 2 diabetes.
What could go wrong: This is a very small, early study with only 20 people. The magnetic device is experimental, and surgery always carries risks like infection or bowel leak. Results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY & OVERWEIGHT OBESITY (DISORDER) TYPE 2 DIABETES (T2DM)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Westmount Surgical Center
RECRUITING

Westmount, Quebec, H3Z 2P9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.